Home Internet of Things Aerospace Apparel Energy Defense Health Care Logistics Manufacturing Retail

RFID News Roundup

MEPS Real-Time announces 500th Intelliguard RFID client installation ••• Harting intros UHF RFID antenna for railway recognition ••• RFID system from Faxitron, Health Beacons Inc. granted FDA clearance for localizing breast lesions ••• Eccel Technology Raspberry Pi board enables RFID, NFC communication ••• Machfu raises $1.6 million to accelerate IIoT deployments in energy, smart water.
By Rich Handley

RFID System from Faxitron, Health Beacons Inc. Granted FDA Clearance for Localizing Breast Lesions

Faxitron, a company that offers solutions for breast health, has announced that the U.S. Food and Drug Administration (FDA) has granted clearance to LOCalizer, a wireless RFID breast lesion localization system manufactured by Health Beacons Inc.

Traditional methods of locating non-palpable breast lesions for removal, such as procedures involving wire localization or radioactive seeds, are encumbered by complex regulations, potential scheduling conflicts, unintended wire migration, and added stress for patients, the company reports. LOCalizer was designed to circumvent these complications by using a non-radioactive, proprietary tag as a marker to enable a surgeon to remove the correct area of breast tissue during a procedure. The tag can be implanted up to 30 days prior to surgery, and can be detected by a mobile handheld reader that can accurately locate tags within millimeters.

"The most exciting aspect of the LOCalizer technology is being able to accurately measure the distance to the target lesion, something we haven't been able to do with other localization methods," said Dr. Christine Dauphine, from the Harbor-UCLA Medical Center, in a prepared statement. "Our team was able to experience the LOCalizer system first-hand in the operating room, and we were thrilled by the prospect of providing patients with a localization method that, by design, could avoid the anxiety of having additional procedures on the day of surgery." Several institutions, including UCLA, will clinically evaluate LOCalizer to compare its benefits to other localization methods.

"As the industry gets better at detecting smaller breast lesions, we must establish a new gold standard for breast lesion localization," said Donogh O'Driscoll, Faxitron's CFO and COO, in the prepared statement. "LOCalizer could be the breakthrough needed to make lumpectomies and breast biopsies safer, more efficient and a better experience for both providers and patients. For more than half a century, our dedication to advancing breast health has been unwavering, and we're honored to once again pave the way for a higher standard of care."

Login and post your comment!

Not a member?

Signup for an account now to access all of the features of RFIDJournal.com!

Case Studies Features Best Practices How-Tos
Live Events Virtual Events Webinars
Simply enter a question for our experts.
RFID Journal LIVE! RFID in Health Care LIVE! LatAm LIVE! Brasil LIVE! Europe RFID Connect Virtual Events RFID Journal Awards Webinars Presentations